Dual-Receptor Agonism Mechanism: It simultaneously activates GLP-1 (Glucagon-like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, thereby enhancing insulin secretion, suppressing glucagon release, and acting on the central nervous system to reduce appetite.
Weight Loss Efficacy: Clinical trials have demonstrated that, following 72 weeks of standardized treatment, overweight or obese patients achieved an average weight reduction of approximately 20% (approximately 22.8 kg). This efficacy surpasses that of single GLP-1 receptor agonists (such as Semaglutide, which yields a 13.7% weight reduction). However, it is important to clarify that there is no single "fastest" or "most effective" weight-loss medication; individual results vary significantly.
Additional Benefits: In addition to weight loss, the treatment also improves glycemic control and reduces cardiovascular risk factors (such as a significant reduction in waist circumference).